Summit Therapeutics Inc
SMMTHealthcare|Biotechnology|USA
$15.25
-0.23 (-1.49%)
Tangible Book
$0.70
Earnings Power
$1.03
About
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Stock Price
-41.1%(1Y)
Pipeline Summary
56 total trials7
Phase 1
27
Phase 2
8
Phase 3
2
Phase 4
Recruiting: 26Completed: 15NOT_YET_RECRUITING: 4Terminated: 3Unknown: 3Active: 5
Active Trials (31)
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors
Phase 1Phase 2Recruiting
Enrollment: 370 participants
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
NCT06567314Cutaneous Squamous Cell Carcinoma
Phase 2Recruiting
Enrollment: 24 participants
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
NCT07535437Non-Small Cell Lung Cancer
Phase 1Phase 2Recruiting
Enrollment: 66 participants
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
NCT07070466Stomach Cancer Stage IV
Phase 2Recruiting
Enrollment: 40 participants
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT06940518Ivonescimab
Phase 2Recruiting
Enrollment: 40 participants
BioScore
2.8/10
High Risk
Ownership
Recent Insider Trades
Zanganeh MahkamBUY
2026-06-123,810,000 shares @ $13.12
DUGGAN ROBERT WBUY
2026-06-123,810,000 shares @ $13.12
Soni Manmeet SinghBUY
2026-06-0450,000 shares @ $14.45
Zanganeh MahkamBUY
2026-06-04100,000 shares @ $14.6
DUGGAN ROBERT WBUY
2026-06-04100,000 shares @ $14.6
Data last updated: Jul 12, 2026, 07:37 PM